NGM Biopharmaceuticals

In a refreshingly transparent disclosure, NGM Bio CEO reveals what led to 33% head count reduction
Fierce Biotech
Wed, 04/5/23 - 11:58 am
NGM Biopharmaceuticals
solid tumors
layoffs
Major readouts on the horizon for small developers
EP Vantage
Fri, 03/31/23 - 10:19 am
Aldeyra Therapeutics
Autolus Therapeutics
Bavarian Nordic
BioXcel Therapeutics
Disc Medicine
Editas Medicine
Immunogen
Lantheus
Mersana Therapeutics
NGM Biopharmaceuticals
Omeros
Roche
Sutro BioPharma
uniQure
Valneva
Viking Therapeutics
Spotlight – What is next in Nash
EP Vantage
Fri, 03/3/23 - 10:02 am
NASH
clinical trials
89Bio
Arrowhead Pharmaceuticals
Can-Fite BioPharma
Ewopharma
Hepagene Therapeutics
JNJ
Ligand Pharmaceuticals
Madrigal Pharmaceuticals
Merck
NGM Biopharmaceuticals
NorthSea Therapeutics
Novartis
Sagimet Biosciences
Terns Pharmaceuticals
Viking Therapeutics
Merck & Co. bails on NGM eye disease collab in wake of phase 2 fail
Fierce Biotech
Wed, 12/21/22 - 11:29 am
Merck
NGM Biopharmaceuticals
clinical trials
eye disease
NGM621
geographic atrophy
NGM’s closely-watched NASH prospect flops, cutting shares in half and spurring R&D rethink
Fierce Biotech
Mon, 05/24/21 - 10:44 am
NGM Biopharmaceuticals
NASH
clinical trials
NGM Bio’s NASH Drug Shows Promise, Shares Rise on Early Phase 2 Data
Xconomy
Tue, 02/25/20 - 12:04 am
NGM Biopharmaceuticals
NASH
clinical trials
aldafermin
5 Biotech Stocks Set to Beat Q3 Earnings Estimates
Yahoo/Zacks.com
Tue, 11/12/19 - 10:20 am
earnings
biotech
Eyenovia
SAGE Therapeutics
AC Immune
Ascendis
NGM Biopharmaceuticals
Early readout from small NGM study shows NASH drug hits liver fat, but shares fall
Fierce Biotech
Mon, 10/7/19 - 11:05 am
NGM Biopharmaceuticals
NASH
clinical trials
FGF19 aldafermin
Back to business for biotech flotations
EP Vantage
Wed, 07/3/19 - 09:48 am
IPOs
BridgeBio
Turning Point Therapeutics
Stoke Therapeutics
Prevail Therapeutics
Atreca
NGM Biopharmaceuticals
Akero Therapeutics
Milestone Pharmaceuticals
Morphic Therapeutics
Karuna
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
Yahoo/Benzinga
Sun, 06/9/19 - 01:36 pm
ADA
Merck
Keytruda
NGM Biopharmaceuticals
NGM313/MK-3655
Corbus Pharmaceuticals
Nektar
Galapagos
Kezar Life Sciences
Kura Oncology
Bluebird Bio
BeiGene
Global Blood Therapeutics
Blueprint Medicines
Regeneron
Arqule
Sunesis
Sutro BioPharma
Incyte
Geron
Forty Seven
NGM Bio’s IPO Raises $107M as NASH Drug Continues Clinical Testing
Xconomy
Wed, 04/3/19 - 11:05 pm
NGM Biopharmaceuticals
IPOs
Merck
March Madness: "The Fabulous 5" Life Science IPOs
BioSpace
Wed, 03/27/19 - 11:49 am
IPOs
Genfit
Silk Road Medical
NGM Biopharmaceuticals
Precision Biosciences
Shockwave Medical
NGM Biopharmaceuticals Updates IPO Filing – Will Raise Over $122 Million
CP Wire
Tue, 03/26/19 - 09:38 am
NGM Biopharmaceuticals
IPOs
Merck
NASH
NGM Biopharmaceuticals Updates IPO Filing – Will Raise Over $122 Million
Tue, 03/26/19 - 09:30 am
NGM Biopharmaceuticals
IPOs
Merck
NASH
Merck doubles down on NGM Bio pact but culls obesity drug
Fierce Biotech
Wed, 03/20/19 - 12:15 pm
Merck
R&D
NGM Biopharmaceuticals
NP201
NASH
obesity
Merck bags global rights to NGM NASH drug, plans phase 2b trial
Fierce Biotech
Thu, 01/3/19 - 09:45 am
Merck
NASH
NGM Biopharmaceuticals
type 2 diabetes
clinical trials
MK-3655
NGM Bio Releases Promising Results From Phase 2 Study Of NGM282 In NASH
CP Wire
Sat, 04/14/18 - 01:20 pm
NGM Biopharmaceuticals
NASH
NGM282
NGM Bio Releases Promising Results From Phase 2 Study Of NGM282 In NASH
Sat, 04/14/18 - 01:21 pm
NGM Biopharmaceuticals
NASH
NGM282
One Year Later: Whatever Happened to Those Biotech Companies?
Forbes
Tue, 04/26/16 - 10:02 am
Atlas Venture
Illumina
Adaptive Biotechnologies
NGM Biopharmaceuticals
Moderna
The 2015 Fierce 15 biotech execs take a bow
Fierce Biotech
Sat, 10/3/15 - 02:01 pm
Alector
Arvinas
CRISPR Therapeutics
Intellia Therapeutics
NGM Biopharmaceuticals
Padlock Therapeutics
SQZ Biotech
Revolution Medicines
Syros Pharmaceuticals
Unum Therapeutics
Yumanity Therapeutics

Pages